Cargando…
Tremor in multiple sclerosis
Tremor is estimated to occur in about 25 to 60 percent of patients with multiple sclerosis (MS). This symptom, which can be severely disabling and embarrassing for patients, is difficult to manage. Isoniazid in high doses, carbamazepine, propranolol and gluthetimide have been reported to provide som...
Autores principales: | , , , |
---|---|
Formato: | Texto |
Lenguaje: | English |
Publicado: |
Steinkopff-Verlag
2007
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC1915650/ https://www.ncbi.nlm.nih.gov/pubmed/17318714 http://dx.doi.org/10.1007/s00415-006-0296-7 |
_version_ | 1782134156694650880 |
---|---|
author | Koch, Marcus Mostert, Jop Heersema, Dorothea De Keyser, Jacques |
author_facet | Koch, Marcus Mostert, Jop Heersema, Dorothea De Keyser, Jacques |
author_sort | Koch, Marcus |
collection | PubMed |
description | Tremor is estimated to occur in about 25 to 60 percent of patients with multiple sclerosis (MS). This symptom, which can be severely disabling and embarrassing for patients, is difficult to manage. Isoniazid in high doses, carbamazepine, propranolol and gluthetimide have been reported to provide some relief, but published evidence of effectiveness is very limited. Most trials were of small size and of short duration. Cannabinoids appear ineffective. Tremor reduction can be obtained with stereotactic thalamotomy or thalamic stimulation. However, the studies were small and information on long-term functional outcome is scarce. Physiotherapy, tremor reducing orthoses, and limb cooling can achieve some functional improvement. Tremor in MS remains a significant challenge and unmet need, requiring further basic and clinical research. |
format | Text |
id | pubmed-1915650 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2007 |
publisher | Steinkopff-Verlag |
record_format | MEDLINE/PubMed |
spelling | pubmed-19156502007-07-13 Tremor in multiple sclerosis Koch, Marcus Mostert, Jop Heersema, Dorothea De Keyser, Jacques J Neurol Review Tremor is estimated to occur in about 25 to 60 percent of patients with multiple sclerosis (MS). This symptom, which can be severely disabling and embarrassing for patients, is difficult to manage. Isoniazid in high doses, carbamazepine, propranolol and gluthetimide have been reported to provide some relief, but published evidence of effectiveness is very limited. Most trials were of small size and of short duration. Cannabinoids appear ineffective. Tremor reduction can be obtained with stereotactic thalamotomy or thalamic stimulation. However, the studies were small and information on long-term functional outcome is scarce. Physiotherapy, tremor reducing orthoses, and limb cooling can achieve some functional improvement. Tremor in MS remains a significant challenge and unmet need, requiring further basic and clinical research. Steinkopff-Verlag 2007-02-21 2007-02 /pmc/articles/PMC1915650/ /pubmed/17318714 http://dx.doi.org/10.1007/s00415-006-0296-7 Text en © Steinkopff Verlag Darmstadt 2007 |
spellingShingle | Review Koch, Marcus Mostert, Jop Heersema, Dorothea De Keyser, Jacques Tremor in multiple sclerosis |
title | Tremor in multiple sclerosis |
title_full | Tremor in multiple sclerosis |
title_fullStr | Tremor in multiple sclerosis |
title_full_unstemmed | Tremor in multiple sclerosis |
title_short | Tremor in multiple sclerosis |
title_sort | tremor in multiple sclerosis |
topic | Review |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC1915650/ https://www.ncbi.nlm.nih.gov/pubmed/17318714 http://dx.doi.org/10.1007/s00415-006-0296-7 |
work_keys_str_mv | AT kochmarcus tremorinmultiplesclerosis AT mostertjop tremorinmultiplesclerosis AT heersemadorothea tremorinmultiplesclerosis AT dekeyserjacques tremorinmultiplesclerosis |